Phase 4 Heart Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who were admitted to hospital primarily because of a sudden worsening of heart failure, confirmed by symptoms plus at least one of: fluid buildup in the lungs seen on exam or chest X-ray, specific measurements on a heart ultrasound, pressure readings from a heart procedure, or elevated heart failure blood markers
• People whose heart's pumping function is reduced (the heart pumps out less than 40% of its blood with each beat), either measured during this hospital stay or within the past 12 months
• People whose heart failure has been present for at least three months and is expected to continue
• People aged 18 years or older
• People who are willing and able to sign a written consent form
• People whose blood test during screening shows elevated inflammation markers (CRP or high-sensitivity CRP above specified levels)

Who may not be able to join:

• People who have other significant health conditions that could affect the study results or how it is carried out, such as a recent heart attack, poorly controlled blood pressure, certain heart rhythm problems, serious lung disease, or nerve and muscle conditions that affect breathing
• People who have had, or have planned during this hospital stay, a heart resynchronisation device implanted, a procedure to open blocked heart arteries, or heart valve surgery within the past three months
• People who have previously had, or are planned to receive, a mechanical heart pump device or a heart transplant
• People who regularly receive heart-strengthening medication through an intravenous drip on an ongoing basis
• People who are currently taking, or have recently taken (within a period based on the specific drug's duration in the body), medicines that suppress the immune system or reduce inflammation (not including common anti-inflammatory pain relievers such as ibuprofen)
• People who are currently taking colchicine, or for whom colchicine is planned to be started within the next three months for gout
• People who have a long-term inflammatory condition such as rheumatoid arthritis or lupus
• People who currently have an active infection of any kind
• People with ongoing or recurring infectious diseases, including hepatitis B, hepatitis C, or HIV/AIDS
• People who have had a cancer diagnosis within the past five years or currently have cancer (with the exception of certain very low-risk, non-spreading lesions — confirm with trial site)
• People with any other condition that means they are not expected to survive at least three months or would be unable to complete the study
• People with severe kidney disease who require dialysis or another form of kidney replacement therapy
• People with abnormally low levels of certain blood cells (white blood cells or platelets, below specified thresholds)
• People who are pregnant (a pregnancy test will be carried out for all biological females who could potentially become pregnant, as part of standard care)
• People who have specific reasons they cannot take colchicine, including: a previous bad reaction to colchicine; a blockage in the bile ducts; significantly reduced kidney function (below a certain filtration rate); or moderate to severe liver scarring (cirrhosis)
• People who are currently incarcerated
• People who are taking certain medications that are not safe to use alongside colchicine, as listed by the US Food and Drug Administration — these include certain HIV medicines (protease inhibitors), certain antibiotics (macrolides), certain antifungal medicines (ketoconazole, fluconazole, itraconazole), a medicine called nefazodone, certain blood pressure or heart medicines (non-dihydropyridine calcium channel blockers), aprepitant, ranolazine, and cyclosporine

Important: Always verify eligibility with the trial site directly before applying.